CSG/TELENOR-DENMARK
23.7.2024 08:31:33 CEST | Business Wire | Press release
Telenor Denmark, the second-largest mobile operator in the Danish market, is a trailblazer for customer-first innovation. To reinforce its position at the forefront of digital telecommunications commerce and continue to provide excellent customer experiences, Telenor Denmark chose CSG®‘s (NASDAQ: CSGS) cloud-native, software-as-a-service (SaaS) platforms to drive its evolution into the future. This transformation turbocharges Telenor Denmark’s omnichannel monetisation, improves business efficiency and future-proofs the B2C and B2B customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722892898/en/
“At Telenor Denmark, we make it easy for our 1.7 million customers to connect with the people and services that matter most to them. This is how we earned the industry’s highest customer satisfaction in 2023,” said Lars Thomsen, CEO, Telenor Denmark. “As we look to the future, we must adapt to meet fluctuating demands and continue to offer new, innovative solutions to our customers. CSG has the proven track record, industry depth and cloud expertise we need to embrace end-to-end digitalisation that will further strengthen our ability to deliver excellent customer service and inspire our customers. It’s an exciting time for Telenor Denmark and this strategic collaboration with CSG brings us one step closer to the future we want to shape for our customers, partners and ourselves.”
As Telenor Denmark and CSG collaborate to make the communication service provider (CSP) a leading digital telco in Denmark, CSG Ascendon, a market-leading AWS cloud-native revenue management platform, with pre-integrated, world-class customer engagement capabilities powered by CSG Xponent, enhance Telenor Denmark’s growth with flexibility, efficiency and intelligence. With CSG’s real-time decisioning engine, Telenor Denmark will deliver better digital experiences across all touchpoints, enhance omnichannel support for all business segments and seize new revenue opportunities. Along with CSG’s industry-leading configure, price and quote capabilities, the two platforms give Telenor Denmark powerful tools to seamlessly bundle offers with partners and create faster, more efficient solutions for its business customers. These improvements make it easy for Telenor Denmark to keep happier, more loyal customers that drive faster revenue for future innovation.
“To come out on top in digital telco commerce, CSPs need business infrastructure that allows them to hit the ground running and wow customers with speed, sophistication and flexibility,” said Ian Waterson, SVP of Go-To-Market, CSG. “As a customer satisfaction leader, Telenor Denmark understands the importance of customer loyalty in driving long-term growth. Their trust in CSG and our industry-leading solutions will elevate customer experience and set Telenor Denmark up for future-ready success.”
Get the facts on CSG Ascendon’s B2C, B2B and B2B2X capabilities and read CSG’s eBook to discover how you can make your CX more proactive, predictive and personalised with data-driven customer communication programs.
About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.
Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.
About Telenor Denmark
Telenor helps Danes create good connections through mobile and internet services. We are committed to being the telecommunications company that provides Danish businesses and consumers with a secure, straightforward, and safe digital everyday life. Therefore, we invest massively in innovation and in developing the Danish telecommunications infrastructure and have recently completed the 5G modernization of our nationwide mobile network.
Telenor is Denmark's second-largest mobile operator and a part of the Telenor Group, operating throughout Scandinavia and Asia. Globally, we assist 186 million customers in their communication needs. In Denmark, we have approximately 1000 employees and 38 stores spread across the country.
You can learn more about us at www.telenor.dk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722892898/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom